Enable Accessibility
Enable Accessibility
Better Health,
Brighter Future
Newsroom
Careers
Contact Us
HCPs
English
français
Canada
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Company Facts
History
Corporate Philosophy
About Takeda Canada
Contact Us
Our Partnerships
Compliance
Takeda Worldwide
What We Do
Our Business
Takeda continues its transformation into an agile and innovative global pharmaceutical leader, serving the needs of patients and physicians worldwide.
Learn more
Conditions We Treat
ADHD
Crohn's Disease
Gastro esophageal reflux disease (GERD, heartburn)
Gaucher Disease
Hereditary Angioedema
Hunter Syndrome
Lung Cancer
Multiple Myeloma
Short Bowel Syndrome
Ulcerative Colitis
Our Medicines
Medications Return Program
Helping Canadian Patients
Our Pipeline of New Treatments
OnePath Patient Support Program
VYVANSE Patient Assistance Program
How Takeda Canada does Business
Canadian R&D Initiatives
Our Stories
Our Stories
Find out Takeda's stories related on Innovation, Caring and Heritage
Learn more
Corporate Responsibility
Takeda's CSR
Takeda is committed to creating corporate value by developing outstanding pharmaceutical products and conducting corporate citizenship activities.
Learn more
Our Commitment
Giving Back to the Community
Product Donations
Grants, Donations and Sponsorships
COVID-19
Newsroom
Careers
Contact Us
HCPs
English
français
Canada
HOME
Newsroom
Share:
Newsroom
News Releases
Newsroom
Recent News Releases
November 4th, 2024
2024-11-04
New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD
September 16th, 2024
2024-09-16
Vatroslav Mateljic Appointed General Manager of Takeda Canada
August 22nd, 2024
2024-08-22
Takeda Releases New Report to Support Health System Readiness for Rare Diseases in Canada
June 21st, 2024
2024-06-21
Takeda’s HyQvia
®
Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older
May 16th, 2024
2024-05-16
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection
See all news releases
SEE ALL GLOBAL NEWS AND RELEASES
TOP
Close